Prokidney Corp (PROK) FinancialsPROKProkidney Corp

Evaluating the bottom line, Prokidney Corp maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -32248.67%, while the net margin is -30957.33%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively PROK converts its operational activities into shareholder value.

In the context of the broader market, PROK competes directly with industry leaders such as ZURA and SCTX. With a market capitalization of $559.30M, it holds a leading position in the sector. When comparing efficiency, PROK's gross margin of 100.00% stands against ZURA's N/A and SCTX's 100.00%. Such benchmarking helps identify whether Prokidney Corp is trading at a premium or discount relative to its financial performance.

ProKidney reported a total revenue of $0.23 million in Q1 2026, which is flat year-over-year but exceeds expectations. However, the company has been consistently reporting net losses, with a net income of -$28.42 million in Q2 2026, reflecting ongoing financial challenges.